SNORA54: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA54

NCBI ID: G677833

SNORA54

Other Name(s): small nucleolar RNA, H/ACA box 54 | Small nucleolar RNA, H/ACA box 54 | ACA54

SNORA54: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known snRNAs is H/ACA box 54 (SNORA54), which is located within the 5'-end of the DNA molecule. The H/ACA box is a specific region of the snRNA that can interact with the histone protein, leading to the formation of a histone-like structure on the microtubules of the mitotic spindle.

SNORA54 is a small RNA molecule that contains 194 amino acid residues and has a calculated molecular mass of 23 kDa. It is primarily localized to the nucleolus, where it interacts with the histone RNA, histone H1, and the A-type microtubule protein. The interaction of SNORA54 with histone H1 and microtubule protein is crucial for the regulation of microtubule dynamics and the proper organization of the nucleolus during the cell cycle.

Drug Target Potential

The potential drug targets of SNORA54 are numerous and varied. One of the primary targets is the inhibition of microtubule dynamics, which can lead to the disruption of the proper organization of the nucleolus and the accumulation of misfolded proteins in the cell. This can result in the formation of aggregates, the disruption of chromosomal stability, and the inhibition of gene expression.

Another potential drug target of SNORA54 is the regulation of the expression of genes involved in the cell cycle, such as those involved in cell growth, apoptosis, and stress response. The regulation of microtubule dynamics by SNORA54 is critical for the proper execution of these processes, and alterations in microtubule dynamics can have a significant impact on cellular behavior.

Biomarker Potential

SNORA54 has the potential to serve as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the primary biomarkers for cancer is the expression of SNORA54, which has been shown to be upregulated in various types of cancer. This upregulation is associated with the poor prognosis of these diseases and may contribute to the development of these diseases.

Another potential biomarker for SNORA54 is its expression level in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The misfolded proteins that accumulate in these diseases are believed to contribute to the pathology, and the regulation of microtubule dynamics by SNORA54 may be involved in the proper execution of these processes.

In conclusion, SNORA54 is a small nucleolar RNA that plays a critical role in the regulation of microtubule dynamics in eukaryotic cells. Its potential drug targets are numerous and varied, including the inhibition of microtubule dynamics and the regulation of the expression of genes involved in the cell cycle. As a biomarker, SNORA54 may be useful in the diagnosis and treatment of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the role of SNORA54 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, H/ACA Box 54

The "SNORA54 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA54 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets